Adjuvant Radiation Therapy for Patients With Type II Endometrial Carcinoma

Yechieli, Raphael; Rasool, Nabila; Robbins, Jared R.; Cogan, Chad; Elshaikh, Mohamed A.

doi:10.1097/igc.0b013e31828b15cb

Cited by 15 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2013, Yechieli et al studied the effect of adjuvant radiation in patients with early-stage type II (UPSC and UCCC) endometrial carcinoma. They showed that RT significantly improved PFS, and there was a trend toward improved 5-year OS regardless of the use of CT or not [11]. Later in 2020 and 2021, two studies suggested that vaginal brachytherapy associated with adjuvant chemotherapy may be a suitable option for patients with stage I UPSC who underwent surgical staging especially those with poor prognostic factors [12,23].…”

Section: Discussionmentioning

confidence: 99%

“…Despite the aggressiveness and the increased risk of recurrence for these subtypes, optimal adjuvant therapy remains controversial, and data on the subject are scarce due to the low number and the heterogenous retrospective cohorts [5,[7][8][9]. Consequently, some of these studies reached contradictory conclusions [10][11][12][13][14][15] and the international guidelines such as the National Comprehensive Cancer Network (NCCN) present substantial variability in the treatment options [16].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Stage I Clear Cell and Serous Uterine Carcinoma: What Is the Right Adjuvant Therapy?

et al. 2023

View full text Add to dashboard Cite

This single-center study aimed to retrospectively evaluate the survival outcomes of patients with FIGO stage I clear cell and serous uterine carcinoma according to the type of adjuvant treatment received. The data were collected between 2003 and 2020 and only patients with stage I clear cell or serous uterine carcinoma treated with primary surgery were included. These were classified into three groups: No treatment or brachytherapy only (G1), radiotherapy +/− brachytherapy (G2), chemotherapy +/− radiotherapy +/− brachytherapy (G3). In total, we included 52 patients: 18 patients in G1, 16 in G2, and 18 in G3. Patients in the G3 group presented with poorer prognostic factors: 83.3% had serous histology, 27.8% LVSI, and 27.8% were FIGO stage IB. Patients treated with adjuvant radiotherapy showed an improved 5-year overall survival (OS) (p = 0.02) and a trend towards an enhanced 5-year progression-free survival (PFS) (p = 0.056). In contrast, OS (p = 0.97) and PFS (p = 0.84) in the chemotherapy group with poorer prognostic factors, were similar with increased toxicity (83.3%). Radiotherapy is associated with improved 5-year OS and tends to improve 5-year PFS in women with stage I clear cell and serous uterine carcinoma. Additional chemotherapy should be cautiously considered in serous carcinoma cases presenting poor histological prognostic factors.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Stage I Clear Cell and Serous Uterine Carcinoma: What Is the Right Adjuvant Therapy?

et al. 2023

View full text Add to dashboard Cite

show abstract

Adjuvant therapy of uterine clear cell carcinoma: a review

Hanna

Elshaikh

2015

Arch Gynecol Obstet

View full text Add to dashboard Cite

For early stage disease, locoregional radiotherapy, especially vaginal brachytherapy, has evidence of efficacy. The therapeutic gain of radiotherapy may be further improved with the addition of systemic chemotherapy. Evidence for combined radiation therapy with systemic chemotherapy in women with advanced stage UCCC has remained debatable. UCCC-specific studies are needed to determine the best adjuvant therapy for UCCC without the confounding effects of USC and other endometrial cancers.

show abstract

Référentiels et techniques d’irradiation de haute précision : cancer de l’endomètre

Jouglar

Barillot

2014

Cancer/Radiothérapie

View full text Add to dashboard Cite

Adjuvant Radiation Therapy for Patients With Type II Endometrial Carcinoma

Cited by 15 publications

References 23 publications

Stage I Clear Cell and Serous Uterine Carcinoma: What Is the Right Adjuvant Therapy?

Stage I Clear Cell and Serous Uterine Carcinoma: What Is the Right Adjuvant Therapy?

Adjuvant therapy of uterine clear cell carcinoma: a review

Référentiels et techniques d’irradiation de haute précision : cancer de l’endomètre

Contact Info

Product

Resources

About